Genetics of Blood Cancers in the U.S. population
Official title: The Rutgers University Study of the Genetics of Blood Cancers
Run by Rutgers, The State University of New Jersey · NCT07714044 · Data updated 2026-11-12
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 110 Years |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Rutgers, The State University of New Jersey Academic / other |
| Locations | 1 site (Piscataway, New Jersey) |
| Status | Recruiting |
| Started | September 22, 2026 |
| Main results expected | August 2029 |
| Study ends | August 2029 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT07714044 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older living in the United States who have internet access and are willing to provide a saliva sample and complete online surveys.
✕Probably not a fit
Individuals who do not benefit directly from this study should not expect personalized medical results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a national online observational study that collects DNA via saliva and surveys to explore genetic variants linked to blood cancers. Participants join remotely, provide consent, and may receive information about their genetic ancestry. The study does not require office visits and invites sharing of electronic health data if participants choose. Monthly newsletters help keep contributors engaged while researchers analyze genetic data to identify known and novel variants related to leukemia, lymphoma, myeloma, and other blood cancers.
Why it matters
Potential benefit: Participants may gain insights into their genetic ancestry and contribute to research that could improve future treatments for blood cancers.
How similar studies have gone: Similar large-scale genetic studies have successfully identified variants associated with blood cancers, supporting the potential value of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 18 years or older * currently living in the United States * have access to the internet and a computer, laptop, tablet or smartphone * willing to provide written informed consent for participation * willing to provide DNA via a saliva sample using a collection kit mailed to your home * willing to complete a survey with questions about health related to the study of blood cancer. Exclusion Criteria: * Not able to meet or fulfill any of the inclusion criteria
Where it's running
-
Rutgers University
Piscataway, New Jersey, United States Recruiting
Study contacts
- Principal investigator: Tara Matise, PhD — Rutgers University
- Study coordinator: Tara Matise, PhD
- Email: rugcc-blood-cancer@rutgers.edu
- Phone: 848-445-3125
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Telehealth music therapy for cognitive difficulties in blood cancer survivors
This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.
-
Evaluating a decision support tool for patients with blood cancers
This study tests a new tool called PRIME to see if it helps older adults with blood cancers make treatment choices that better match their personal preferences compared to regular care.
-
Targeting measurable residual AML with tagraxofusp plus azacitidine and venetoclax
This trial tests whether adding tagraxofusp to azacitidine and venetoclax can safely help control measurable residual acute myeloid leukemia (AML) in adults who are in remission but still have detectable disease.
-
Home blood transfusions for people with advanced blood cancers in hospice
The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.
-
Prophylactic use of Tocilizumab to prevent complications after CAR-T therapy
This study is testing if giving Tocilizumab before or during CAR-T therapy can help prevent serious side effects like cytokine release syndrome and neurotoxicity in patients with B-cell cancers.
-
Platform for Rare Blood Disorders in Europe
This study is trying to gather and share information about rare blood disorders across Europe to help researchers understand these conditions better and improve treatment options for patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.